Progenics Pharma (PGNX) Misses Q2 EPS by 3c

Progenics Pharma (NASDAQ: PGNX) reported Q2 EPS of ($0.17), $0.03 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $1.63 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• InspireMD (NSPR) Tops Q2 EPS by 1c
• XP Inc eyes US banking license as next business step